Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Transplant nephrology
How do you approach kidney transplant evaluation and management in an ESKD patient with a history of anti-GBM disease and currently detectable anti-GBM antibodies?
Related Questions
How do you approach the management of patients with primary membranous nephropathy and a positive anti-PLA2R antibody test who are being considered for kidney transplantation?
Do you recommend 24 hour urine stone risk studies for patients with no history of nephrolithiasis who are undergoing evaluation as potential kidney donors?
How long do you wait for a reduction in EBV viral load after reducing immunosuppression before deciding to start rituximab in a kidney transplant patient with EBV viremia?
How have you incorporated donor-derived cell-free DNA to help with the diagnosis of rejection or monitoring of the treatment response to rejection?
When do you recommend genetic testing prior to kidney transplantation for a patient with ESKD secondary to FSGS?
Would you recommend routinely checking ANCA levels just prior to a planned kidney transplantation in patients with a history of ESKD secondary to ANCA-associated vasculitis?
How has your approach to managing asymptomatic bacteriuria in kidney transplant patients changed in light of a recent meta-analysis showing no significant differences in pyelonephritis, symptomatic UTI, or graft loss between patients treated with antibiotics and those who were not treated?
How much proteinuria would warrant consideration of native kidney nephrectomies at the time of a kidney transplant?
Should a patient who requires definitive treatment for prostate cancer as a pre-transplant requirement be strictly required to complete their course prior to transplant/initiation of immunosuppression?
How do you approach chronic active AMR concurrent with changes of CNI toxicity?
